Clinical Trial Update: Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT) [Phase 2, Phase 3]

View source ↗

Summary

An update on a Phase 2/3 trial evaluating levofloxacin as prophylaxis after allogeneic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Levaquin (levofloxacin)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Malignancy, Allogeneic Stem Cell Transplantation | Phase 2, Phase 3 | Status: UNKNOWN